We would love to hear your thoughts about our site and services, please take our survey here.
The shots are direct competitors to Actimel, which can only claim immune benefits through their content of Vits B and D6. They actually make no health claim for the bacteria because it doesn't seem possible to scientifically prove there are any
Another alternative could be that the royalty is paid to DSM on future productions of Fruitflow, therefore beco9ming an invisible cost of goods in the accounts. No doubt DSM still demand their usual secrecy to throw potential buyers noff the scent of what their margins are.
It's a legitimate question, and one that I hope is possible for us to see an answer to. Not that I'm holding my breath over though.
Mol42
I think you are misreading some of the results
I agree that a 60k outflow is good news, but this will swing up and down in future reports according to stock levels and debtors v inflows.
The increase in debtors is solely down to the new business to business sales model. A further increase would be a welcome sign so long as sales volumes keep growing. This would be easier to finance without equity raises.
Extended terms are normal within industry, in my own trade 90 days is normal, 120/150 days are frequently offered to encourage larger stock holdings.
The main goal has to be adding more brands, especially more powerful ones, and they do demand favourable terms.
Just normal business IMHO
More or less agree with those comments.
Reasonably good sales, and sales pipeline, whilst we wasit for: a/ DSM to develop and commercialise a new area of health benefit (years away), and b/ ByHealth to get started with their undoubtedly strong marketing skills. (near term se hop)
I think sphinx is correct that the sentiment has been a fear of a fundraising for a long time now, causing those who would consider buying more shares to pause. In the main, this is countered by a very small amount of sellers. An illiquid share trade situation doesn't do anyone a favour, This stasis has to be broken, either by the aforesaid cash raise, or by one of several other potential funding arrangements being announced. It's more that obvious that substantial sales to high credit rated clients would be relatively easy to insure by invoice discounting, credit finance, overdraft, export credit guarantee, factoring, blah blah. More than one way? That's an understatement, but certainty wouldn't half be useful to us holders to know.
With possible vast expansion of volume probable upon passing regulations in China, Mr Ford will have had funding that right at the top of his agenda. The opinion of a miniscule holding failed investor venting his spleen on a chat board isn't worth his time reading, that's for sure.
The webinar is explaining the seismic date, which has been validated by the drills so far, presented by the geologist who has a vast amount of experience and knowledge of the terrain. There ARE billions of barrels of oil in that domain.
Utterly dishonest to describe the acquisition of billions of barrels of oil as "hot air"
It is a material change in the potential value of the company..
If you're in to correlations, why is it that when you, in all your ID's, claim a drastic fall is coming, the sp rises strongly soon after. If you are trying to keep the shorter solvent, you'd be better shutting up.
Official, 19th Oct RNS
he plan targets FID (final investment decision) by the end of 2025 with first production to follow in early 2026. Estimated costs to first production are conservatively estimated at $120 million, based on:
· $20 million for the hot tap
· $20 million for facilities upgrade (including preparing Alkaid-2 for injection service)
· $60 million for the first three production wells
· $20 million for three years of corporate G&A
This cost to reach first production contrasts with other developments in the region, requiring at least an order of magnitude greater expenditure. Additional development costs after first production are expected to be funded through debt or equivalent sources. The Company will provide further updates on its financing activities, designed to minimize equity or other value dilution for existing investors, as arrangements progress.
In order to achieve the stated goals, insti investors will be needed. This appointment facilitates that. It also make a US market listing more likely.
Anyone that suggests it is anything but a positive move is spreading lies.
The Louis/kever/rogadar multi ID tactics are purely an attempt to dissuade potential buyers in order to mitigate losses for shorters. Who's to say they won't succeed. The plan laid out by the company requires patience, something often lacking in PI's. I'll be adding more, but judging timing isn't easy, because we've all had the heads up that funding agreements could drop at any time. DH has said that their priority is to protect the shareholders interests, and his skin in the game is proof that he means just that.